

PRIOR AUTHORIZATION POLICY

- POLICY:** Alpha₁-Proteinase Inhibitor Products Prior Authorization Policy
- Aralast NP® (alpha₁-proteinase inhibitor [human] intravenous infusion – Shire)
 - Glassia® (alpha₁-proteinase inhibitor [human] intravenous infusion – Shire)
 - Prolastin®-C and Prolastin®-C Liquid (alpha₁-proteinase inhibitor [human] intravenous infusion – Grifols Therapeutics)
 - Zemaira® (alpha₁-proteinase inhibitor [human] intravenous infusion – CSL Behring)

REVIEW DATE: 11/17/2021

OVERVIEW

Alpha₁-proteinase inhibitor (also known as alpha₁-antitrypsin [AAT]), is indicated for use as a chronic augmentation and maintenance therapy in adults with **alpha₁-proteinase deficiency and clinical evidence of emphysema**.¹⁻⁵ The following products are available commercially in the US: Prolastin-C (also available as Prolastin-C Liquid), Aralast NP, Zemaira, and Glassia. The products vary in their availability and in some of their purification and viral inactivation processes.

Disease Overview

AAT deficiency is a rare, chronic, hereditary, autosomal co-dominant disorder marked by low concentrations of AAT which leads to progressive, severe emphysema that often does not manifest until the third to fourth decades of life.¹ Treatment is aimed at raising serum levels of AAT above a theoretical protective threshold of 11 mcM (mcmol/L); epidemiological data suggest lower probability of chronic obstructive pulmonary disease (COPD) above this level.⁶ Of note, older laboratory techniques (e.g., radial immunodiffusion) measured non-purified levels of AAT, which tend to overestimate the concentration by 35% to 40%. To distinguish between non-purified and purified standards, the former are expressed in mg/dL and the latter are expressed in mcM. An AAT level of 80 mg/dL measured by radial immunodiffusion corresponds to a plasma AAT level of 11 mcM. Alpha₁-proteinase inhibitor is the only treatment approved to correct AAT deficiency.

Guidelines

A European Respiratory Society (ERS) statement addresses diagnosis and treatment of pulmonary disease in AAT deficiency (2017).⁸ It is noted that augmentation therapy has been shown to reduce progression of emphysema in severe AAT deficiency. There is no evidence to support efficacy of AAT augmentation therapy for current smokers of any phenotype. These guidelines support earlier American Thoracic Society (ATS)/ERS guidelines (2003) which state that intravenous augmentation therapy is recommended for individuals with established airflow obstruction from AAT deficiency.⁷

The Canadian Thoracic Society updated its guidelines (2012) regarding AAT deficiency testing and augmentation therapy.⁹ The guidelines state that evidence supports the consideration of AAT augmentation therapy in non-smoking or ex-smoking patients with COPD due to emphysema and a documented AAT deficiency (level ≤ 11 mcmol/L). Patients should also be receiving other pharmacological and non-pharmacologic therapies, including comprehensive case management and pulmonary rehabilitation.

The Medical and Scientific Advisory Committee of the Alpha-1 Foundation guidelines (2016) provide similar recommendations.¹⁰ Intravenous AAT augmentation is strongly recommended in non-smoking or ex-smoking patients with forced expiratory volume (FEV₁) 30 to 65% of predicted due to well-documented benefit in this group. Weaker recommendations also support treatment of patients with FEV₁ below 30%



of predicted or above 65% of predicted. Usual management of COPD should also be provided, with strong emphasis on facilitating tobacco cessation. Of note, AAT replacement therapy is not recommended for patients who continue to smoke.

Other Uses with Supportive Evidence

In the ATS/ERS 2003 guidelines, it is stated that AAT replacement therapy is a reasonable option for AAT deficiency-associated panniculitis.⁷ Although no controlled trials provide a clear treatment recommendation, augmentation therapy with purified human alpha₁-proteinase inhibitor or fresh frozen plasma to restore plasma and local tissue levels of AAT appears to be rational, safe, and effective. In a review of treatment options for panniculitis in AAT deficiency, augmentation therapy with alpha₁-proteinase inhibitor was noted to be the most successful medical treatment.¹¹

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of alpha₁-proteinase inhibitor. All approvals are provided for the duration noted below.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of alpha₁-proteinase inhibitor (e.g., Aralast NP, Glassia, Prolastin-C, Prolastin-C Liquid, Zemaira) is recommended in those who meet one of the following criteria:

FDA-Approved Indication

1. **Alpha₁-Antitrypsin Deficiency with Emphysema (or Chronic Obstructive Pulmonary Disease).** Approve for 1 year if the patient meets the following criteria (A, B, and C):

- A) Patient is ≥ 18 years of age; AND
- B) Patient has a baseline (pretreatment) alpha₁-antitrypsin serum concentration of < 80 mg/dL or 11 mM (11 mmol/L); AND
- C) According to the prescriber, the patient is a current non-smoker.

Other Uses with Supportive Evidence

2. **Alpha₁-Antitrypsin Deficiency-Associated Panniculitis.** Approve for 1 year if the patient is ≥ 18 years of age.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of alpha₁-proteinase inhibitor is not recommended in the following situations:

1. **Alpha₁-Antitrypsin Deficiency without Lung Disease, even if Deficiency-Induced Hepatic Disease is Present.** The ATS/ERS standards for the diagnosis and management of individuals with AAT deficiency (2003) state that the pathophysiology of liver disease in AAT deficiency is different from that of lung disease, and the use of alpha₁-proteinase inhibitor is not discussed for these patients.⁷ There is an absence of information that suggests alpha₁-proteinase inhibitor is useful in patients with AAT deficiency-related liver disease.
2. **Bronchiectasis (without alpha₁-antitrypsin deficiency).** Studies have not demonstrated alpha₁ proteinase inhibitor to be effective for this condition. The ATS/ERS standards for the diagnosis and

management of individuals with AAT deficiency (2003) state that despite the well-recognized association between AAT deficiency and the early development of emphysema, only a limited number of studies have assessed the association between AAT deficiency and bronchiectasis.⁷ Studies suggest that bronchiectasis is more a result of emphysematous changes in the parenchyma than of AAT deficiency.

3. **Chronic Obstructive Pulmonary Disease (COPD) without Alpha₁-Antitrypsin Deficiency.** The Global Initiative for Chronic Obstructive Lung Disease guidelines for the diagnosis, management, and prevention of COPD (updated 2021) state that never or ex-smokers with an FEV₁ of 35 to 60% of predicted may be most suitable for AAT deficiency augmentation therapy; newer evidence suggests that individuals with higher FEV₁ values may also be candidates.¹² However, this therapy is not recommended for COPD that is unrelated to AAT deficiency.
4. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Aralast NP® intravenous infusion [prescribing information]. Lexington, MA: Shire; December 2018.
2. Zemaira® intravenous infusion [prescribing information]. Kankakee, IL: CSL Behring; April 2019.
3. Prolastin®-C intravenous infusion [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics; June 2018.
4. Prolastin®-C Liquid intravenous infusion [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics; August 2018.
5. Glassia® intravenous infusion [prescribing information]. Lexington, MA: Shire; June 2017.
6. Brantly ML, Lascano JE, Shahmohammadi A. Intravenous alpha-1 antitrypsin therapy for alpha-1 antitrypsin deficiency: the current state of the evidence. *Chronic Obstr Pulm Dis*. 2018;6(1):100-114.
7. American Thoracic Society and the European Respiratory Society. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. *Am J Respir Crit Care Med*. 2003;168:818-900.
8. Miravittles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in alpha-1-antitrypsin deficiency. *Eur Respir J*. 2017;50(5).
9. Marciniuk DD, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: A Canadian Thoracic Society clinical practice guideline. *Can Respir J*. 2012;19:109-116.
10. Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. *Chronic Obstr Pulm Dis*. 2016;3(3):668-682.
11. Sabbagh DK, Barmayehvar B, Nguyen T, Edgar RG, Turner AM. Managing panniculitis in alpha-1 antitrypsin deficiency: systematic review of evidence behind treatment. *World J Dermatol*. 2018;7(1):1-8
12. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2021. Available at: <https://goldcopd.org/2021-gold-reports/>. Accessed on November 10, 2021.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	Alpha₁-Antitrypsin Deficiency with Emphysema (or Chronic Obstructive Pulmonary Disease): A criterion was added to specify that the patient must be ≥ 18 years of age, in alignment with product labeling. Alpha₁-Antitrypsin Deficiency-Associated Panniculitis: A criterion was added requiring that the patient be ≥ 18 years of age.	10/21/2020
Annual Revision	Conditions Not Recommended for Approval: “Cystic Fibrosis” was removed from Conditions Not Recommended for Approval.	11/17/2021

PreferredOne Community Health Plan Nondiscrimination Notice

PreferredOne Community Health Plan ("PCHP") complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. PCHP does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

PCHP:

Provides free aids and services to people with disabilities to communicate effectively with us, such as:

- Qualified sign language interpreters
- Written information in other formats (large print, audio, accessible electronic formats, other formats)

Provides free language services to people whose primary language is not English, such as:

- Qualified interpreters
- Information written in other languages

If you need these services, contact a Grievance Specialist.

If you believe that PCHP has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:

Grievance Specialist
PreferredOne Community Health Plan
PO Box 59052
Minneapolis, MN 55459-0052
Phone: 1.800.940.5049 (TTY: 763.847.4013)
Fax: 763.847.4010
customerservice@preferredone.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, a Grievance Specialist is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at:

U.S. Department of Health and Human Services
200 Independence Avenue, SW
Room 509F, HHH Building
Washington, D.C. 20201
1-800-368-1019, 800-537-7697 (TDD)

Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.

Language Assistance Services

ATTENTION: If you do not speak English, language assistance services, free of charge, are available to you. Call 1.800.940.5049 (TTY: 763.847.4013).

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1.800.940.5049 (TTY: 763.847.4013).

LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 1.800.940.5049 (TTY: 763.847.4013).

XIYYEEFFANNAA: Afaan dubbattu Oroomiffa, tajaajila gargaarsa afaanii, kanfaltiidhaan ala, ni argama. Bilbilaa 1.800.940.5049 (TTY: 763.847.4013).

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1.800.940.5049 (TTY: 763.847.4013).

注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 1.800.940.5049 (TTY: 763.847.4013)。

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1.800.940.5049 (телетайп: 763.847.4013).

ໂປດຊາບ: ຖ້າວ່າ ທ່ານເວົ້າພາສາລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໂດຍບໍ່ເສຍຄ່າ ຈະມີພ້ອມໃຫ້ທ່ານ. ໂທ 1.800.940.5049 (TTY: 763.847.4013).

ማስታወሻ: የሚናገሩት ቋንቋ አማርኛ ከሆነ የትርጉም እርዳታ ድርጅቶች፡ በነጻ ሊያገዝዎት ተዘጋጅተዋል፡ ወደ ሚከተለው ቁጥር ይደውሉ 1.800.940.5049 (መስማት ለተሳናቸው: 763.847.4013) .

ဟံသာဝတီ- နမူနာတို့ ကညီ ကျိအသိ, နမူနာ ကျိအတိအကျတို့ တလက်ကွက်လက်စွာ နှိတ်မိသည့်သို့လို့လိ။ ကိ: 1.800.940.5049 (TTY: 763.847.4013).

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1.800.940.5049 (TTY: 763.847.4013).

ប្រយ័ត្ន: បើសិនជាអ្នកនិយាយភាសាខ្មែរ, សេវាជំនួយភាសា ដោយមិនគិតថ្លៃ គឺអាចមានសំរាប់អ្នក។ ជូរ ទូរស័ព្ទ 1.800.940.5049 (TTY: 763.847.4013)។

ملحوظة: إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 1.800.940.5049 (رقم هاتف الصم والبكم: 763.847.4013).

ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 1.800.940.5049 (TTY: 763.847.4013).

주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1.800.940.5049 (TTY: 763.847.4013). 번으로 전화해 주십시오.

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 1.800.940.5049 (TTY: 763.847.4013).

PreferredOne Insurance Company Nondiscrimination Notice

PreferredOne Insurance Company ("PIC") complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. PIC does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

PIC:

Provides free aids and services to people with disabilities to communicate effectively with us, such as:

- Qualified sign language interpreters
- Written information in other formats (large print, audio, accessible electronic formats, other formats)

Provides free language services to people whose primary language is not English, such as:

- Qualified interpreters
- Information written in other languages

If you need these services, contact a Grievance Specialist.

If you believe that PIC has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:

Grievance Specialist
PreferredOne Insurance Company
PO Box 59212
Minneapolis, MN 55459-0212
Phone: 1.800.940.5049 (TTY: 763.847.4013)
Fax: 763.847.4010
customerservice@preferredone.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, a Grievance Specialist is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at:

U.S. Department of Health and Human Services
200 Independence Avenue, SW
Room 509F, HHH Building
Washington, D.C. 20201
1-800-368-1019, 800-537-7697 (TDD)

Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.

Language Assistance Services

ATTENTION: If you do not speak English, language assistance services, free of charge, are available to you. Call 1.800.940.5049 (TTY: 763.847.4013).

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1.800.940.5049 (TTY: 763.847.4013).

LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 1.800.940.5049 (TTY: 763.847.4013).

XIYEEFFANNAA: Afaan dubbattu Oroomiffa, tajaajila gargaarsa afaanii, kanfaltiidhaan ala, ni argama. Bilbilaa 1.800.940.5049 (TTY: 763.847.4013).

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1.800.940.5049 (TTY: 763.847.4013).

注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 1.800.940.5049 (TTY: 763.847.4013)。

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1.800.940.5049 (телетайп: 763.847.4013).

បំពេញ: ប្រសិនបើ អ្នកនិយាយភាសាខ្មែរ, សេវាជំនួយភាសា ដោយមិនគិតថ្លៃ គឺអាចមានសំរាប់អ្នក។ ហៅ 1.800.940.5049 (TTY: 763.847.4013).

ማስታወሻ: የሚናገሩት ቋንቋ አማርኛ ከሆነ የትርጉም እርዳታ ድርጅቶች፡ በነጻ ሊያገኙበት ተዘጋጅተዋል፡ ወደ ሚከተለው ቁጥር ይደውሉ 1.800.940.5049 (ማስማት ለተሳናቸው: 763.847.4013) .

ဟံသာဝတီ: နမူနာတို့ ကညီ ကျိအဆိ, နမူနာ ကျိအဆိတော်မရစေလော တလက်ကွက်လက်စွာ နိတမံဘဉ်သုန့်လိ။ ကိ: 1.800.940.5049 (TTY: 763.847.4013).

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1.800.940.5049 (TTY: 763.847.4013).

ប្រយ័ត្ន: បើសិនជាអ្នកនិយាយភាសាខ្មែរ, សេវាជំនួយភាសា ដោយមិនគិតថ្លៃ គឺអាចមានសំរាប់អ្នក។ ហៅ 1.800.940.5049 (TTY: 763.847.4013).

ملحوظة: إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 1.800.940.5049 (رقم هاتف الصم والبكم: 763.847.4013).

ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 1.800.940.5049 (TTY: 763.847.4013).

주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1.800.940.5049 (TTY: 763.847.4013). 번으로 전화해 주십시오.

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 1.800.940.5049 (TTY: 763.847.4013).